Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
In conclusion, CAM levels are associated with psoriasis diagnosis and MetS may influence E-selectin and PAI-1 concentrations.
|
31758356 |
2020 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Women with MetS had higher values of PAI-1 (36.0 ± 19.1 vs 19.3 ± 14.8 ng/mL, p < .001); in contrast, no differences were observed when compared by hormonal status (20.7 ± 18.10 vs 20.2 ± 17.0 ng/mL, NS).
|
31023101 |
2019 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
To compare circulating pigment epithelium derived factor (PEDF) levels in type 2 diabetes patients (T2D) with and without metabolic syndrome (MetS+/-) to healthy controls and assess PEDF association with plasminogen activator inhibitor-1 (PAI-1) and von Willebrand factor (vWF) as markers of endothelial dysfunction.
|
30904010 |
2019 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
A tendency to increase the inflammatory markers IL-6 (p = 0.069) and MCP-1 (p = 0.067) was observed in those patients suffering from MS. An increase in the cardiovascular risk markers PAI-1 (p = 0.007) and triglycerides/HDL cholesterol ratio (p < 0.0001) was also found in the MS group.
|
30924020 |
2019 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
We demonstrated that the increase of sICAM-1, sVCAM-1 and PAI-1, together with decrease of omentin-1 led to a proinflammatory imbalance pointing to the presence of subclinical atherosclerosis, and improving CVD risk stratification in non-smoking patients at early stage MetS beyond traditional scores.
|
31349950 |
2019 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Elevated PAI-1 antigen levels have been identified as a potential biomarker for coronary artery disease and metabolic syndrome while being modulated by a number of atherosclerotic risk factors.
|
29494856 |
2018 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
In addition, PAI-1 values correlated significantly with metabolic syndrome components and carotid IMT.
|
28822973 |
2018 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Cell adhesion molecules and plasminogen activator inhibitor type-1 (PAI-1) in patients with rheumatoid arthritis: influence of metabolic syndrome.
|
30008151 |
2018 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
There were significant associations between metabolic syndrome (MetS) and E-selectin and PAI-1.
|
29400123 |
2018 |
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The elevated level of plasminogen activator inhibitor-1 (PAI-1) in obese subjects with metabolic syndrome and in patients with type 2 diabetes is well established.
|
30002679 |
2018 |
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Plasma PAI-1 antigen and activity levels are associated with increased body mass index and with features of the insulin resistance syndrome like obesity and diabetes.
|
28605281 |
2017 |
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Subjects with T2DM plus MetS have elevated PAI-1 levels before clinical manifestations of atherothrombotic disease.
|
28271069 |
2017 |
Metabolic Syndrome X
|
0.300 |
Therapeutic
|
disease |
RGD |
Pioglitazone in adult rats reverses immediate postnatal overfeeding-induced metabolic, hormonal, and inflammatory alterations.
|
26084260 |
2015 |
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The current study tried to investigate in parallel the association of PAI-1 activity with the PAI-1 4G/5G polymorphism, with MI, and some components of metabolic syndrome (MetS).
|
24695040 |
2014 |
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to analyze the allele and genotype frequencies of these polymorphisms in PAI-1 gene and its association with metabolic syndrome and its components in a sample of Mexican mestizo children.
|
22459021 |
2012 |
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Valsartan reduced plasma PAI-1 levels compared to non-RAS inhibitor in hypertensive patients with MetS, which suggests it may be useful for improving fibrinolytic function.
|
22451451 |
2012 |
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Its predictive ability for MetS and T2DM should not be assessed independently of PAI-1 levels.
|
21800006 |
2011 |
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Plasma IL-6, PAI-1 and TNFα levels were higher in MS. P2X(7)R mRNA and protein, identified in both VAT and SAT, were more abundant in MS than in CTL.
|
21978920 |
2011 |
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We have investigated the expression of PAI-1, IL-6 and IL-18 in subcutaneous adipose tissue (AT) of subjects with (n = 22) and without (n = 36) MetS.
|
21842238 |
2011 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Adipose tissue macrophages: a piece of the PAI of metabolic syndrome.
|
20371488 |
2010 |
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Accordingly, beneficial pleiotropic effects of statins on coronary artery disease may be attributable, in part, to attenuation of overexpression of PAI-1 mediated by the 3'-UTR in syndromes of insulin resistance (such as the metabolic syndrome) and type 2 diabetes.
|
20299979 |
2010 |
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Contribution of genetic and metabolic syndrome to omental adipose tissue PAI-1 gene mRNA and plasma levels in obesity.
|
20127289 |
2010 |
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.
|
19619703 |
2009 |
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Metabolic syndrome-related factors had little influence on PAI-1 levels in White subjects but in African and Indians subjects these variables had a major influence on PAI-1 levels in those with the 5G/5G genotype but not in subjects with the 4G/4G genotype.
|
17467713 |
2008 |
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Circulating plasminogen activator inhibitor-1 levels are elevated at an early stage of impaired glucose tolerance, resulting in diabetes and metabolic syndrome.
|
18160587 |
2008 |